Merck & Company Gets a Buy Rating from BMO Capital


In a report released today, Alex Arfaei from BMO Capital assigned a Buy rating to Merck & Company (NYSE: MRK), with a price target of $70. The company’s shares opened today at $59.54.

According to TipRanks.com, Arfaei is a 4-star analyst with an average return of 4.9% and a 65.3% success rate. Arfaei covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Bristol Myers, and AstraZeneca.

Merck & Company has an analyst consensus of Moderate Buy, with a price target consensus of $67.33.

See today’s analyst top recommended stocks >>

Based on Merck & Company’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $10.14 billion and net profit of $736 million. In comparison, last year the company earned revenue of $9.34 billion and had a net profit of $1.55 billion.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on MRK:

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts